Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors

Publisher： Karger

E-ISSN： 1423-0232|62|3|216-222

ISSN： 0030-2414

Source： Oncology, Vol.62, Iss.3, 2002-06, pp. : 216-222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Dose Escalation Study of Pegylated Liposomal Doxorubicin (Caelyx) in Combination with Capecitabine (Xeloda) in Patients with Refractory Solid Tumors

By  

Oncology, Vol. 69, Iss. 6, 2006-02 ,pp. : 463-469

Karger

Access to resources Recommend Favorite

Phase I Study of Weekly Docetaxel and Liposomal Doxorubicin in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 69, Iss. 3, 2005-10 ,pp. : 202-207

Karger

Access to resources Recommend Favorite

A Dose-Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 190-196

Karger

Access to resources Recommend Favorite

Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer

By  

Oncology, Vol. 70, Iss. 2, 2006-05 ,pp. : 141-146

Karger

Access to resources Recommend Favorite

A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors

By  

Oncology, Vol. 61, Iss. 4, 2001-11 ,pp. : 265-270

Karger

Access to resources Recommend Favorite